2-73572357-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001378454.1(ALMS1):βc.10480C>Tβ(p.Gln3494Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000647 in 1,608,160 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001378454.1 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALMS1 | NM_001378454.1 | c.10480C>T | p.Gln3494Ter | stop_gained | 16/23 | ENST00000613296.6 | NP_001365383.1 | |
ALMS1 | NM_015120.4 | c.10483C>T | p.Gln3495Ter | stop_gained | 16/23 | NP_055935.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALMS1 | ENST00000613296.6 | c.10480C>T | p.Gln3494Ter | stop_gained | 16/23 | 1 | NM_001378454.1 | ENSP00000482968 | P3 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152140Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000452 AC: 11AN: 243456Hom.: 0 AF XY: 0.0000531 AC XY: 7AN XY: 131896
GnomAD4 exome AF: 0.0000680 AC: 99AN: 1456020Hom.: 0 Cov.: 31 AF XY: 0.0000649 AC XY: 47AN XY: 723918
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74320
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 20, 2024 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Also known as c.10477C>T p.Gln3493*; This variant is associated with the following publications: (PMID: 19440062, 33197640, 28402684, 26066530, 24462884, 17594715, 30064963, 29718281, 25846608, 26704672, 16720663, 22043170, 18195218, 28610912, 11941370) - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Mar 30, 2023 | - - |
Alstrom syndrome Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jan 14, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change creates a premature translational stop signal (p.Gln3495*) in the ALMS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALMS1 are known to be pathogenic (PMID: 17594715). This variant is present in population databases (rs772624348, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with Alstrββm syndrome (PMID: 11941370, 24462884, 28402684). It has also been observed to segregate with disease in related individuals. This variant is also known as p.Gln3494*. ClinVar contains an entry for this variant (Variation ID: 210122). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Mar 11, 2024 | Criteria applied: PVS1,PM3_STR,PM2_SUP,PP4; Identified as compund heterozygous with NM_001378454.1:c.11669-1G>A - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 16, 2021 | The p.Q3495* pathogenic mutation (also known as c.10483C>T), located in coding exon 16 of the ALMS1 gene, results from a C to T substitution at nucleotide position 10483. This changes the amino acid from a glutamine to a stop codon within coding exon 16. This mutation has been detected in the homozygous state and in the compound heterozygous state with other ALMS1 mutations in individuals reported to have Alstrom syndrome, and has been reported to segregate with disease in a kindred (Hearn T et al. Nat Genet, 2002 May;31:79-83; Paisey RB et al. Eur J Med Genet, 2014 Feb;57:71-5; Cruz-Aguilar M et al. Genet Test Mol Biomarkers, 2017 Jun;21:397-401; Dotan G et al. Ophthalmic Genet Jan;38:440-445). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at